Biomarin: Interest in new dwarfism drug for children exceeds expectations

Following European approval, interest in Biomarin's treatment for children with achondroplasia, Voxzogo, beats company expectations, it reports. US approval could be coming next month.

Photo: Rob Acket/EMA

Ascendis might gain strong competition in the shape of Biomarin's new treatment for achondroplasia, also known as dwarfism.

In any case, the US-based pharmaceutical company Biomarin reports that European interest in the drug is up, even if the company only booked USD 100,000 for Q3 sales of the drug.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs